Hsien-Feng Lin1,2, Kuan-Fu Liao3,4,5, Ching-Mei Chang6, Cheng-Li Lin7,8, Shih-Wei Lai9,10. 1. School of Chinese Medicine, China Medical University, Taichung, Taiwan. 2. Department of Family Medicine, China Medical University Hospital, No 2, Yuh-Der Road, Taichung City, 404, Taiwan. 3. Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan. 4. College of Medicine, Tzu Chi University, Hualien, Taiwan. 5. Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. 6. Department of Nursing, Tungs' Taichung Metro Habor Hospital, Taichung, 435, Taiwan. 7. College of Medicine, China Medical University, Taichung, Taiwan. 8. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan. 9. Department of Family Medicine, China Medical University Hospital, No 2, Yuh-Der Road, Taichung City, 404, Taiwan. wei@mail.cmuh.org.tw. 10. College of Medicine, China Medical University, Taichung, Taiwan. wei@mail.cmuh.org.tw.
Abstract
BACKGROUND/ OBJECTIVE: Little is known about the relationship between proton pump inhibitors use and pyogenic liver abscess. The objective of this study was to evaluate the correlation between proton pump inhibitors use and pyogenic liver abscess in Taiwan. METHODS: This was a population-based case-control study using the database of the Taiwan National Health Insurance Program since 2000 to 2011. Subjects aged 20 to 84 who experienced their first episode of pyogenic liver abscess were enrolled as the case group (n = 1372). Randomly selected subjects aged 20 to 84 without pyogenic liver abscess were enrolled as the control group (n = 1372). Current use, early use, and late use of proton pump inhibitors was defined as subjects whose last one tablet for proton pump inhibitors was noted ≤30 days, between 31 to 90 days and ≥91 days before the date of admission for pyogenic liver abscess. Subjects who never received a prescription for proton pump inhibitors were defined as nonusers of proton pump inhibitors. A multivariable unconditional logistic regression model was used to measure the odds ratio and 95% confidence interval to evaluate the correlation between proton pump inhibitors use and pyogenic liver abscess. RESULTS: After adjusting for confounders, the adjusted odds ratio of pyogenic liver abscess was 7.59 for subjects with current use of proton pump inhibitors (95% confidence interval 5.05, 11.4), when compared with nonusers. CONCLUSIONS: Current use of proton pump inhibitors is associated with a greater risk of pyogenic liver abscess.
BACKGROUND/ OBJECTIVE: Little is known about the relationship between proton pump inhibitors use and pyogenic liver abscess. The objective of this study was to evaluate the correlation between proton pump inhibitors use and pyogenic liver abscess in Taiwan. METHODS: This was a population-based case-control study using the database of the Taiwan National Health Insurance Program since 2000 to 2011. Subjects aged 20 to 84 who experienced their first episode of pyogenic liver abscess were enrolled as the case group (n = 1372). Randomly selected subjects aged 20 to 84 without pyogenic liver abscess were enrolled as the control group (n = 1372). Current use, early use, and late use of proton pump inhibitors was defined as subjects whose last one tablet for proton pump inhibitors was noted ≤30 days, between 31 to 90 days and ≥91 days before the date of admission for pyogenic liver abscess. Subjects who never received a prescription for proton pump inhibitors were defined as nonusers of proton pump inhibitors. A multivariable unconditional logistic regression model was used to measure the odds ratio and 95% confidence interval to evaluate the correlation between proton pump inhibitors use and pyogenic liver abscess. RESULTS: After adjusting for confounders, the adjusted odds ratio of pyogenic liver abscess was 7.59 for subjects with current use of proton pump inhibitors (95% confidence interval 5.05, 11.4), when compared with nonusers. CONCLUSIONS: Current use of proton pump inhibitors is associated with a greater risk of pyogenic liver abscess.
Authors: C P C de Jager; P C Wever; E F A Gemen; M G H van Oijen; A B van Gageldonk-Lafeber; P D Siersema; G C M Kusters; R J F Laheij Journal: Aliment Pharmacol Ther Date: 2012-10-03 Impact factor: 8.171
Authors: Shih Wei Lai; Kuan Fu Liao; Hsueh Chou Lai; Pang Yao Tsai; Fung Chang Sung; Pei Chun Chen Journal: Ann Acad Med Singapore Date: 2013-03 Impact factor: 2.473